Vor Biopharma (VOR) investor relations material

Executive summary

• Telitacicept, a dual-target fusion protein for autoimmune diseases, is in global Phase 3 trials for generalized myasthenia gravis (gMG) and Sjögren's disease (SjD), with topline gMG data expected in 1H 2027.

• Enrollment is progressing for both Phase 3 trials, and telitacicept is positioned as a foundational therapy for B-cell driven autoimmune diseases.

• In-licensed telitacicept from RemeGen in June 2025, assuming global development (ex-China) and commercialization rights.

• Clinician feedback supports upstream B-cell modulation in myasthenia gravis, aligning with telitacicept's mechanism.

• Significant operating losses continue, with net loss of $219.6 million for Q1 2026 and accumulated deficit of $1,372.6 million.

Financial highlights

• Q1 2026 net loss: $219.6 million, compared to $32.5 million in Q1 2025, mainly due to changes in fair value of liability-classified warrants.

• Cash, cash equivalents, and marketable securities totaled $491.5 million as of March 31, 2026, projected to fund operations into early 2029.

• Research and development expenses: $17.6 million in Q1 2026, down $9.1 million year-over-year, mainly due to reduced spend on legacy programs and lower headcount.

• General and administrative expenses: $17.6 million in Q1 2026, up $11.0 million year-over-year, driven by higher stock-based compensation and personnel costs.

• Net proceeds of $74.9 million from March 2026 private placement.

Outlook and guidance

• Cash runway projected into early 2029 based on current operating plan.

• Topline data from global Phase 3 gMG trial expected in first half of 2027.

• Global development programs for telitacicept aim to support regulatory approvals in the US, Europe, and Japan.

• Ongoing evaluation of telitacicept in additional indications and continued investment in clinical development.